BR112023024815A2 - Composição de vacina, composição ou kit de vacina para induzir uma resposta imune e regime de vacinação - Google Patents
Composição de vacina, composição ou kit de vacina para induzir uma resposta imune e regime de vacinaçãoInfo
- Publication number
- BR112023024815A2 BR112023024815A2 BR112023024815A BR112023024815A BR112023024815A2 BR 112023024815 A2 BR112023024815 A2 BR 112023024815A2 BR 112023024815 A BR112023024815 A BR 112023024815A BR 112023024815 A BR112023024815 A BR 112023024815A BR 112023024815 A2 BR112023024815 A2 BR 112023024815A2
- Authority
- BR
- Brazil
- Prior art keywords
- vaccine composition
- nucleic acid
- antigen
- vectors
- inducing
- Prior art date
Links
- 229960005486 vaccine Drugs 0.000 title abstract 8
- 230000028993 immune response Effects 0.000 title abstract 3
- 230000001939 inductive effect Effects 0.000 title abstract 3
- 238000002255 vaccination Methods 0.000 title abstract 3
- 239000000427 antigen Substances 0.000 abstract 10
- 102000036639 antigens Human genes 0.000 abstract 10
- 108091007433 antigens Proteins 0.000 abstract 10
- 150000007523 nucleic acids Chemical class 0.000 abstract 7
- 102000039446 nucleic acids Human genes 0.000 abstract 7
- 108020004707 nucleic acids Proteins 0.000 abstract 7
- 239000013598 vector Substances 0.000 abstract 6
- 239000002671 adjuvant Substances 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000001165 lymph node Anatomy 0.000 abstract 1
- 210000004324 lymphatic system Anatomy 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
- A61K2039/55527—Interleukins
- A61K2039/55533—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
composição de vacina, composição ou kit de vacina para induzir uma resposta imune e regime de vacinação. a presente invenção refere-se a uma composição de vacina compreendendo (1) um primeiro conjunto de um ou mais vetores compreendendo um ácido nucleico que codifica um ou mais adjuvantes, em que o primeiro conjunto de um ou mais vetores são vetores adenovirais, e (2) um antígeno ou uma combinação de antígenos ou um ácido nucleico que codifica o referido antígeno ou a combinação de antígenos ou um segundo conjunto de um ou mais vetores compreendendo o referido ácido nucleico. a invenção diz respeito ainda à referida composição de vacina para uso no tratamento ou profilaxia de uma doença. além disso, a invenção diz respeito a uma composição de vacina ou kit de vacina para induzir uma resposta imune compreendendo (1) um primeiro ácido nucleico que codifica um ou mais adjuvantes ou um primeiro conjunto de um ou mais vetores compreendendo o referido primeiro ácido nucleico e (2) um antígeno ou uma combinação de antígenos ou um segundo ácido nucleico que codifica o referido segundo antígeno ou a combinação de antígenos ou um segundo conjunto de um ou mais vetores compreendendo o referido segundo ácido nucleico, em que (1) é administrado a um paciente em um primeiro local e (2) é administrado ao paciente em um segundo local, em que o primeiro local é o mesmo ou está dentro de 20 cm do segundo local; e o sistema linfático do primeiro e do segundo local drena para os mesmos linfonodos. a invenção também diz respeito a um regime de vacinação compreendendo uma primeira etapa de administração que compreende a administração de um antígeno e um adjuvante codificado, e uma segunda etapa de administração que compreende a administração de um antígeno e/ou um adjuvante codificado.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21180661 | 2021-06-21 | ||
| PCT/EP2022/066733 WO2022268722A1 (en) | 2021-06-21 | 2022-06-20 | Vaccine composition comprising encoded adjuvant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023024815A2 true BR112023024815A2 (pt) | 2024-02-20 |
Family
ID=76553531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023024815A BR112023024815A2 (pt) | 2021-06-21 | 2022-06-20 | Composição de vacina, composição ou kit de vacina para induzir uma resposta imune e regime de vacinação |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4358998A1 (pt) |
| KR (1) | KR20240024800A (pt) |
| CN (1) | CN117915940A (pt) |
| AU (1) | AU2022299252A1 (pt) |
| BR (1) | BR112023024815A2 (pt) |
| CA (1) | CA3221363A1 (pt) |
| IL (1) | IL308826A (pt) |
| WO (1) | WO2022268722A1 (pt) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE449105T1 (de) | 2004-01-23 | 2009-12-15 | Angeletti P Ist Richerche Bio | Impfstoffträger für schimpansen-adenovirus |
| ES2898235T3 (es) | 2009-02-02 | 2022-03-04 | Glaxosmithkline Biologicals Sa | Secuencias de aminoácidos y de ácidos nucleicos de adenovirus de simio, vectores que las contienen, y sus usos |
| US20190381157A1 (en) * | 2017-01-29 | 2019-12-19 | Zequn Tang | Methods of immune modulation against foreign and/or auto antigens |
| KR20190107954A (ko) * | 2018-03-13 | 2019-09-23 | 건국대학교 산학협력단 | 돼지 인터루킨 2를 발현하는 재조합 아데노바이러스 벡터 |
| US20210379170A1 (en) | 2018-11-15 | 2021-12-09 | Nouscom Ag | Selection of cancer mutations for generation of a personalized cancer vaccine |
-
2022
- 2022-06-20 EP EP22735152.5A patent/EP4358998A1/en active Pending
- 2022-06-20 BR BR112023024815A patent/BR112023024815A2/pt unknown
- 2022-06-20 IL IL308826A patent/IL308826A/en unknown
- 2022-06-20 WO PCT/EP2022/066733 patent/WO2022268722A1/en active Application Filing
- 2022-06-20 AU AU2022299252A patent/AU2022299252A1/en active Pending
- 2022-06-20 CA CA3221363A patent/CA3221363A1/en active Pending
- 2022-06-20 KR KR1020237042003A patent/KR20240024800A/ko unknown
- 2022-06-20 CN CN202280043507.8A patent/CN117915940A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3221363A1 (en) | 2022-12-29 |
| IL308826A (en) | 2024-01-01 |
| KR20240024800A (ko) | 2024-02-26 |
| EP4358998A1 (en) | 2024-05-01 |
| AU2022299252A1 (en) | 2023-11-23 |
| WO2022268722A1 (en) | 2022-12-29 |
| CN117915940A (zh) | 2024-04-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Teo | Review of COVID-19 vaccines and their evidence in older adults | |
| Frey et al. | Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults | |
| BR112022024248A2 (pt) | Vacinas de combinação à base de ácido nucleico | |
| Khorasani et al. | Evaluation of the efficacy of a new oil-based adjuvant ISA 61 VG FMD vaccine as a potential vaccine for cattle | |
| EA200701786A1 (ru) | Поливалентная противогриппозная иммуногенная композиция | |
| BR112020011593A2 (pt) | Uma vacina para proteção contra streptococcus suis | |
| HRP20120331T1 (hr) | Postupak sprječavanja ili liječenja infekcije bakterijom m. tuberculosis | |
| Cherry et al. | Atypical measles in children previously immunized with attenuated measles virus vaccines | |
| CL2008002559A1 (es) | Construccion que comprende un vector de fluorocarbono y un antigeno del virus de la influenza; composicion farmaceutica que lo comprende; y su uso para aumentar la respuesta inmunologica | |
| Hu et al. | A two-dose optimum for recombinant S1 protein-based COVID-19 vaccination | |
| ES2568071T3 (es) | Dianas novedosas de Acinetobacter baumannii | |
| Litinsky et al. | Vaccination against influenza in patients with systemic sclerosis | |
| Gigley et al. | Long-term immunity to lethal acute or chronic type II Toxoplasma gondii infection is effectively induced in genetically susceptible C57BL/6 mice by immunization with an attenuated type I vaccine strain | |
| BR112023024815A2 (pt) | Composição de vacina, composição ou kit de vacina para induzir uma resposta imune e regime de vacinação | |
| Correia et al. | Exuberant lichenoid eruption after Oxford–AstraZeneca COVID‐19 vaccine: a singular case. | |
| Ramirez et al. | CpG improves influenza vaccine efficacy in young adult but not aged mice | |
| Lamas et al. | Optimization of an inactivated vaccine against a scuticociliate parasite of turbot: effect of antigen, formalin and adjuvant concentration on antibody response and protection against the pathogen | |
| Desclozeaux et al. | Safety and immunogenicity of a prototype anti-Chlamydia pecorum recombinant protein vaccine in lambs and pregnant ewes | |
| Choi et al. | An open-label, comparative, single dose, clinical Phase Ⅰ study to assess the safety and immunogenicity of typhoid conjugate vaccine (Vi-CRM197) in healthy Filipino adults | |
| Tabynov et al. | Safety of the novel influenza viral vector Brucella abortus vaccine in pregnant heifers | |
| Tarro | On the End of a Nightmare (COVID-19). The Role of the Immune System | |
| Sengler et al. | Survey about tolerance of the AS03-adjuvanted H1N1 influenza vaccine in children with rheumatic diseases | |
| BR112020011831A2 (pt) | vacina para proteção contra streptococcus suis | |
| Yasuda et al. | Frequent nasal administrations of recombinant cholera toxin B subunit (rCTB)-containing tetanus and diphtheria toxoid vaccines induced antigen-specific serum and mucosal immune responses in the presence of anti-rCTB antibodies | |
| Rappuoli | Changing route: aerosol vaccine against tuberculosis |